OR WAIT 15 SECS
Rousselot announced that it will launch two related products at the event: StabiCaps, a gelatin solution for more stable soft gels, and Peptan IIm, a hydrolyzed collagen Type II matrix developed specifically for joint health.
In keeping with the “New perspectives in the pharma & nutraceutical world” theme of its 2018 Innovation Days event, global gelatin and collagen peptide producer Rousselot (Son, Netherlands) announced that it will launch two related products at the event: StabiCaps, a gelatin solution for more stable soft gels, and Peptan IIm, a hydrolyzed collagen Type II matrix developed specifically for joint health.
The first day of the two-day event-taking place March 14th and 15th at Rousselot’s Expertise Centre in Ghent, Belgium-will focus on the company’s pharmaceutical innovations and the role of excipients in capsule production, while also highlighting the new StabiCaps, patented gelatins specially developed for superior shell stability and active pharmaceutical ingredient (API) release.
Claude Capdepon, EMEA application laboratory director, Rousselot, noted in a press statement: "We have conducted extensive research into the parameters that cause cross-linking in gelatin and we have developed a specific testing protocol to understand gelatin behavior over time in the presence of cross-linkers. The tests we conducted on several gelatins, including those marketed with reduced cross-linking claims, were very clear: StabiCaps shows superior stability in the presence of cross-linkers, optimal dissolution of the shell and API release among other factors.”
On day two, attendees will learn about current developments in the joint health market and be introduced to the latest product in Rousselot’s Peptan range, Peptan IIm, a natural, hydrolyzed collagen type II matrix that the company calls “an all-round joint health ingredient that offers multiple benefits” for consumers aiming to improve joint health. The ingredient’s supporting science and related unpublished research will also be available for attendees to examine.
According to Lisette van Lith, global director for Peptan, "Peptan IIm is the ultimate solution for joint health, healthy aging and mobility as it represents exactly what consumers are looking for. The combination of short- and long-term benefits makes all the difference in repeat purchases. At the same time, its effectiveness at low dosage makes it extremely easy to use in tablets, capsules, and to formulate with and integrate into everyday diets.”